Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Next Previous
Trial Profile

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Vertex Pharmaceuticals

Most Recent Events

  • 23 Sep 2021 Results deriving results from NCT02347657 and other study; developing a prediction model and projecting the impact of introducing ELEX/TEZ/IVA on this outcome measure, published in the Thorax
  • 20 May 2021 Outcomes of a validated, lifetime, patient-level simulation model build using data from the IVA/TEZ/ELX Phase 3b study (NCT04105972) and TEZ/IVA Phase 3 study (NCT02347657), were presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
  • 12 Mar 2019 According to a Vertex Pharmaceuticals media release, based on the data from EVOLVE and EXPAND studies, the Therapeutic Goods Administration (TGA) of Australia has granted registration to SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top